Takeda Pharmaceutical Obtains Additional Approval for Its Peptic Ulcer Agent.Tokyo, Japan, June 19, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical announced on June 16 that it obtained additional approval for Takepron (lansoprazole) Capsules 15/ OD Tablets, its proprietary peptic ulcer peptic ulcer: see ulcer. peptic ulcer Sore that develops in the mucous membrane of the stomach (more frequent in women) or duodenum (accounting for 80% of ulcers and more frequent in men) when its ability to resist acid in gastric juice is reduced. agent, from the Ministry of Health, Labor and Welfare. Currently indicated for the treatments of gastric ulcer, duodenal ulcer as well as an adjunct to Helicobacter pylori eradication, Takepron is now available for the treatment of non-erosive gastroesophageal reflux disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. . A proton pump inhibitor proton pump inhibitor n. A class of drugs that inhibit gastric acid secretion by interfering with the movement of hydrogen ions across cell membranes and are used mainly to treat peptic ulcers, gastroesophageal reflux disease, and esophagitis. discovered by Takeda Pharmaceutical, Takepron is marketed in over 90 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion